To ensure that biotechnologically produced drugs are not recognized as foreign by the immune system and eliminated prematurely from the body, biotechnology uses different methods for modifying them so that effective drug delivery is possible.
celares gmbh is specialized in modifying biopharmaceuticals with polyethylene glycols (PEG), through which active ingredients have a longer effect in the body and are more soluble. Whereas in this technology the ingredients are chemically coupled with PEG, Alrise Biosystems GmbH encapsulates biotechnological ingredients with a microparticle envelope. This envelope prevents the drugs from decomposing in the liver, but instead allows them to be released in a controlled manner into the body.
The above technologies not only reduce side effects; the drugs also need to be taken less frequently.
Drug delivery is not only interesting for newly developed substances: Biopharmaceuticals already on the market can gain new patent protection with the aid of a new form of administration.
"Drivers for Germany's Future Sustainability"
The UNIPRENEURS Initiative has recognized the entrepreneurial spirit of 20 professors, among them ECRC researcher Simone Spuler. As a co-founder of the startup MyoPax, she is pioneering stem cell tech...more ...
Eckert & Ziegler Continues Positive Sales Development in the First Half of 2023
Eckert & Ziegler Strahlen- und Medizintechnik AG (ISIN DE0005659700, TecDAX) increased its sales by 10% to € 118.0 million in the first half of 2023.more ...
Biosynth Expands Capabilities with Acquisition of celares, Experts in Bioconjugation and Specialty Polymers
Biosynth, a supplier of critical raw materials to the life science industry, is pleased to announce today that it has acquired celares, a leader in the development and manufacture of conjugate vaccine...more ...
Explore Precision Medicine Event im Futurium
Das Gläserne Labor beteiligt sich am 9. Oktober 2023 am Explore Precision Medicine Event im Futurium mit Workshops und Präsentationen.more ...